Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold

The constitutively active tyrosine kinase BCR-ABL is the underlying cause of chronic myeloid leukemia (CML). Current CML treatments rely on the long-term use of tyrosine kinase inhibitors (TKIs), which target the ATP binding site of BCR-ABL. Over the course of treatment, 20–30% of CML patients devel...

Full description

Saved in:
Bibliographic Details
Published in:Sci Rep
Main Authors: Huang, Yen-Hua, Henriques, Sónia T., Wang, Conan K., Thorstholm, Louise, Daly, Norelle L., Kaas, Quentin, Craik, David J.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532999/
https://ncbi.nlm.nih.gov/pubmed/26264857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12974
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items